In 1935 Domagk described his experiments with a sulfanilamide compound and inspired the medical profession to renewed activity in combating bacterial infections with chemotherapy. About a year later Colebrook proclaimed that sulfanilamide was practically a specific for infections due to the beta type of hemolytic streptococcus. Since that time sulfanilamide has been widely used against infections caused by a variety of organisms. Derivatives of the drug have been developed and, like the parent substance, have also been extensively used. Much has been written on this phase of chemotherapy, not only to advocate the use of sulfanilamide and its derivatives, but also to point out possible dangers associated with their administration.
It was only natural that sulfanilamide should have received an early and general reception in the field of otolaryngology, where the hemolytic streptococcus plays such a prominent part in disease. Since the introduction of this drug and its derivatives there
STUART EA. ACUTE SUPPURATIVE OTITIS MEDIA: A REVIEW OF CASES ENCOUNTERED DURING A FIVE YEAR PERIOD. Arch Otolaryngol. 1941;33(5):734–748. doi:10.1001/archotol.1941.00660030744007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: